Intensified methotrexate, vinblastine, doxorubicin and cisplatin (I-MVAC) with or without panitumumab as first-line treatment of advanced urothelial carcinoma in patients without H-Ras nor K-Ras mutations. Randomised phase II study.

Trial Profile

Intensified methotrexate, vinblastine, doxorubicin and cisplatin (I-MVAC) with or without panitumumab as first-line treatment of advanced urothelial carcinoma in patients without H-Ras nor K-Ras mutations. Randomised phase II study.

Active, no longer recruiting
Phase of Trial: Phase II

Latest Information Update: 18 Feb 2017

At a glance

  • Drugs Panitumumab (Primary) ; Cisplatin; Doxorubicin; Methotrexate; Vinblastine
  • Indications Urogenital cancer
  • Focus Therapeutic Use
  • Most Recent Events

    • 18 Feb 2017 Results presented at the 2017 Genitourinary Cancers Symposium
    • 03 Apr 2012 Actual initiation date (26 Feb 2010) added as reported by European Clinical Trials Database.
    • 09 Jun 2011 New trial record
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top